Tags

Type your tag names separated by a space and hit enter

Contemporary narrative review of treatment options for COVID-19.
Respirology. 2021 08; 26(8):745-767.R

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is ongoing and many drugs have been studied in clinical trials. From a pathophysiological perspective, anti-viral drugs may be more effective in the early stage while immunomodulators may be more effective in severe patients in later stages of infection. While drugs such as lopinavir-ritonavir, hydroxychloroquine and azithromycin have proved to be ineffective in randomized controlled trials, corticosteroids, neutralizing monoclonal antibodies, remdesivir, tocilizumab and baricitinib have been reported to benefit certain groups of patients with COVID-19. In this review, we will present the key clinical evidence and progress in promising COVID-19 therapeutics, as well as summarize the experience and lessons learned from the development of the current therapeutics.

Authors+Show Affiliations

Beijing University of Chinese Medicine, Beijing, China. Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China. Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China.Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore. National Centre for Infectious Diseases, Singapore. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. Yong Loo Lin School of Medicine, National University of Singapore, Singapore.Beijing University of Chinese Medicine, Beijing, China. Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China. Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China. Tsinghua University-Peking University Joint Center for Life Sciences, Beijing, China. Department of Respiratory Medicine, Capital Medical University, Beijing, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

34240518

Citation

Shang, Lianhan, et al. "Contemporary Narrative Review of Treatment Options for COVID-19." Respirology (Carlton, Vic.), vol. 26, no. 8, 2021, pp. 745-767.
Shang L, Lye DC, Cao B. Contemporary narrative review of treatment options for COVID-19. Respirology. 2021;26(8):745-767.
Shang, L., Lye, D. C., & Cao, B. (2021). Contemporary narrative review of treatment options for COVID-19. Respirology (Carlton, Vic.), 26(8), 745-767. https://doi.org/10.1111/resp.14106
Shang L, Lye DC, Cao B. Contemporary Narrative Review of Treatment Options for COVID-19. Respirology. 2021;26(8):745-767. PubMed PMID: 34240518.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Contemporary narrative review of treatment options for COVID-19. AU - Shang,Lianhan, AU - Lye,David Chien, AU - Cao,Bin, Y1 - 2021/07/08/ PY - 2021/05/23/received PY - 2021/06/07/accepted PY - 2021/7/10/pubmed PY - 2021/7/27/medline PY - 2021/7/9/entrez KW - COVID-19 KW - baricitinib KW - convalescent plasma KW - corticosteroid KW - neutralizing monoclonal antibody KW - remdesivir KW - tocilizumab SP - 745 EP - 767 JF - Respirology (Carlton, Vic.) JO - Respirology VL - 26 IS - 8 N2 - The coronavirus disease 2019 (COVID-19) pandemic is ongoing and many drugs have been studied in clinical trials. From a pathophysiological perspective, anti-viral drugs may be more effective in the early stage while immunomodulators may be more effective in severe patients in later stages of infection. While drugs such as lopinavir-ritonavir, hydroxychloroquine and azithromycin have proved to be ineffective in randomized controlled trials, corticosteroids, neutralizing monoclonal antibodies, remdesivir, tocilizumab and baricitinib have been reported to benefit certain groups of patients with COVID-19. In this review, we will present the key clinical evidence and progress in promising COVID-19 therapeutics, as well as summarize the experience and lessons learned from the development of the current therapeutics. SN - 1440-1843 UR - https://www.unboundmedicine.com/medline/citation/34240518/Contemporary_narrative_review_of_treatment_options_for_COVID-19. L2 - https://doi.org/10.1111/resp.14106 DB - PRIME DP - Unbound Medicine ER -